Chemotherapy as a Salvage Strategy After Immunotherapy Failure in Advanced Hepatocellular Carcinoma: A Case Series - 18/04/26
, Gonca Eldem 2, Sevtap Arslan Sarıkaya 2, Şuayib Yalçın 1, Omer Dizdar 1Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights |
• | The role of chemotherapy after immunotherapy failure in advanced hepatocellular carcinoma is not well defined. |
• | We report a case series of patients with advanced hepatocellular carcinoma treated with chemotherapy after progression on immunotherapy. |
• | Gemcitabine- and fluorouracil-based regimens resulted in clinical and radiologic responses in selected patients. |
• | Chemotherapy was generally well tolerated in patients with preserved liver function and good performance status. |
• | Chemotherapy may remain a therapeutic option after immunotherapy failure in selected advanced hepatocellular carcinoma patients. |
Abstract |
The role of systemic chemotherapy after immunotherapy failure in advanced hepatocellular carcinoma (HCC) remains poorly defined. We describe five patients with advanced HCC who progressed on immune checkpoint inhibitor–based therapy and subsequently received cytotoxic chemotherapy. Gemcitabine-, fluorouracil-, and platinum-based chemotherapy regimens, including hepatic arterial infusion chemotherapy in one patient, were administered.
Three patients achieved a partial radiologic response, whereas two showed early disease progression. These descriptive observations suggest that, in carefully selected patients with preserved liver function and good performance status, chemotherapy may be associated with radiologic disease control after immunotherapy failure.
Le texte complet de cet article est disponible en PDF.Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
